Baystate Wealth Management LLC Cellectis S.A. Transaction History
Baystate Wealth Management LLC
- $1.36 Billion
- Q4 2023
A detailed history of Baystate Wealth Management LLC transactions in Cellectis S.A. stock. As of the latest transaction made, Baystate Wealth Management LLC holds 500 shares of CLLS stock, worth $865. This represents 0.0% of its overall portfolio holdings.
Number of Shares
500Holding current value
$865% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding CLLS
# of Institutions
31Shares Held
11.2MCall Options Held
5.9KPut Options Held
1.4K-
Long Focus Capital Management, LLC San Juan, PR4.62MShares$7.99 Million0.36% of portfolio
-
Capital International Investors Los Angeles, CA1.85MShares$3.2 Million0.0% of portfolio
-
Ubs Asset Management Americas Inc Chicago, IL1.44MShares$2.49 Million0.0% of portfolio
-
Credit Suisse Ag Zurich, V81.44MShares$2.49 Million0.0% of portfolio
-
Baillie Gifford & CO694KShares$1.2 Million0.0% of portfolio
About Cellectis S.A.
- Ticker CLLS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 45,510,800
- Market Cap $78.7M
- Description
- Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatm...